Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
80.28
+3.39 (4.41%)
At close: Nov 13, 2026, 4:00 PM EST
81.22
+0.94 (1.17%)
After-hours: Nov 13, 2026, 7:30 PM EST

Tarsus Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
682.2451.36182.9517.4525.8257.03
Revenue Growth
86.34%146.71%948.62%-32.42%-54.73%-
Gross Profit
571.55356.35116.74-34.46-17.7613.24
Operating Income
-65.54-70.97-120.57-143.16-62.71-12.16
Net Income
-702.23-66.42-115.55-135.89-62.09-13.83
Earnings Per Share
-16.00-1.59-3.07-4.62-2.52-0.67
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
309.61417.27291.38227.44217.03171.82
Total Debt
89.4383.0472.4530.2220.161.19
Net Cash (Debt)
220.18334.23218.92197.23196.87170.62
Net Cash Growth
-31.05%52.67%11.00%0.18%15.38%1.99%
Net Cash Per Share
5.028.005.826.718.008.30

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
49.9-12.45-83.03-117.49-49.033.75
Capital Expenditures
-17.46-9.86-1.57-1.5-0.51-0.59
Free Cash Flow
32.44-22.31-84.59-119-49.543.16
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
83.78%78.95%63.81%-197.50%-68.81%23.22%
Operating Margin
-9.61%-15.72%-65.90%-820.53%-242.92%-21.32%
Pretax Margin
-101.21%-14.26%-63.16%-778.89%-240.53%-24.15%
Profit Margin
-102.94%-14.71%-63.16%-778.89%-240.51%-24.25%
FCF Margin
4.75%-4.94%-46.24%-682.04%-191.88%5.54%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-97.48----
P/FCF Ratio
122.01----147.13
PS Ratio
5.807.7011.5738.4215.158.16